Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database

Purpose To determine the prognostic role of tamoxifen therapy for patients with ductal carcinoma in situ (DCIS) according to molecular subtypes. Methods Data of 14,944 patients with DCIS were analyzed. Molecular subtypes were classified into four categories based on expression of estrogen receptor (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2018-06, Vol.169 (2), p.311-322
Hauptverfasser:	Hwang, Ki-Tae, Kim, Eun-Kyu, Jung, Sung Hoo, Lee, Eun Sook, Kim, Seung Il, Lee, Seokwon, Park, Heung Kyu, Kim, Jongjin, Oh, Sohee, Kim, Young A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Analysis Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer research Carcinoma, Intraductal, Noninfiltrating - drug therapy Carcinoma, Intraductal, Noninfiltrating - genetics Carcinoma, Intraductal, Noninfiltrating - pathology Clinical Trial Disease-Free Survival Ductal carcinoma in situ Epidermal growth factor Epidermal growth factors ErbB-2 protein Estrogen receptors Estrogens Female Humans Kaplan-Meier Estimate Medical prognosis Medicine Medicine & Public Health Middle Aged Multivariate analysis Oncology Patient outcomes Progesterone Receptor, ErbB-2 - genetics Receptors, Estrogen - genetics Receptors, Progesterone - genetics Registries Survival Analysis Tamoxifen Tamoxifen - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose To determine the prognostic role of tamoxifen therapy for patients with ductal carcinoma in situ (DCIS) according to molecular subtypes. Methods Data of 14,944 patients with DCIS were analyzed. Molecular subtypes were classified into four categories based on expression of estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Kaplan–Meier estimator was used for overall survival analysis while Cox proportional hazards model was used for univariate and multivariate analyses. Results Luminal A subtype (ER/PR+, HER2−) showed higher ( P = .009) survival rate than triple-negative (TN) subtype. Tamoxifen therapy group showed superior ( P
ISSN:	0167-6806 1573-7217
DOI:	10.1007/s10549-018-4681-6